eLaws
|
eCases
|
United States Code
|
Federal Courts
|
Sign In
Sign Up
eLaws
eCases »
United States Code
Federal Courts »
Home
»
Rulemaking
» Draft Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability
Draft Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability
Document ID:
FDA-2008-D-0413-0001
Document Type:
Notice
Agency:
Food And Drug Administration
Topics:
No Topics associated with this document
Federal Register Number:
E8-18127
View Document:
Details Information
Document Subtype:
NAD-Notice of Availability of Data
Received Date:
August 06 2008, at 09:27 AM Eastern Daylight Time
Start-End Page:
46020 - 46021
Page Count:
2
Comment Start Date:
October 6 2008, at 09:27 AM Eastern Standard Time
Comments
View All
Total:
12
AstraZeneca - Comment
Posted:
09/30/2008
ID:
FDA-2008-D-0413-0003
Comment Period Closed
sanofi-aventis - Comment
Posted:
10/03/2008
ID:
FDA-2008-D-0413-0005
Comment Period Closed
IPEC - Comment
Posted:
10/07/2008
ID:
FDA-2008-D-0413-0008
Comment Period Closed
International Pharmaceutical Excipients Council of the Americas - Comment
Posted:
10/07/2008
ID:
FDA-2008-D-0413-0009
Comment Period Closed
BASF Corporation (BC) - Comment
Posted:
10/08/2008
ID:
FDA-2008-D-0413-0010
Comment Period Closed
Related Documents
Total:
0
No documents available.
Draft Guidance for Industry on Residual Solvents in Drug Products Marketed in the United States; Availability
Details Information
Comments
View AllPosted: 09/30/2008 ID: FDA-2008-D-0413-0003
Posted: 10/03/2008 ID: FDA-2008-D-0413-0005
Posted: 10/07/2008 ID: FDA-2008-D-0413-0008
Posted: 10/07/2008 ID: FDA-2008-D-0413-0009
Posted: 10/08/2008 ID: FDA-2008-D-0413-0010
Related Documents